Skip to content

Glenmark Pharma’s Goa branch receives a warning from USFDA

The company added that it intends to collaborate closely with the USFDA and is dedicated to resolving the matter within the allotted period.

Source: Official website of Glenmark Pharmaceuticals.

The Goa manufacturing plant of Glenmark Pharma has been served a warning letter by the US Food & Drug Administration (USFDA) as they had previously issued an 'Official Action Indicated '(OAI). The Glenmark factory in Goa was visited by the officials of the US drug regulator in May 2022 for a general inspection.

"Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in furtherance to intimation dated 26th August, 2022 for United States Food and Drug Administration (USFDA) inspection of our Goa manufacturing facility, we wish to inform you that the Company has received a communication from the USFDA that the classification of Company's said facility continues to be as Official Action Indicated ('OAI')," Glenmark said in a statement.

This post is for paying subscribers only


Already have an account? Log in